Amneal grants RSUs to Co-CEO Chintu Patel

Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals Co-CEO Chintu Patel reported equity awards of restricted stock units. On March 2, 2026, he received 190,632 restricted stock units, each representing a contingent right to one share of Class A common stock, vesting in four equal annual installments beginning March 2, 2027.

He was also granted 354,031 performance-based restricted stock units tied to average closing price targets over a three-year performance period. The award can pay out from 0% to 200% of the 354,031 target shares, with any earned units vesting in full on February 28, 2029, representing the maximum number of shares issuable under this grant.

Insider Trade Summary

Grant/Award: 544,663 shares

Grant/Award 2 txns

Insider Patel Chintu

Role Co-CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	190,632	$0.00	$0.00
Grant/Award	Performance-Based Restricted Stock Units	354,031	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 190,632 contracts (Direct); Performance-Based Restricted Stock Units — 354,031 contracts (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
2. F2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.
3. F3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
4. F4. Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

FAQ

What insider equity awards did Amneal (AMRX) Co-CEO Chintu Patel receive?

Chintu Patel received 190,632 restricted stock units and 354,031 performance-based restricted stock units. Each unit represents a contingent right to one share of Amneal’s Class A common stock under the company’s equity compensation arrangements.

How do the new Amneal (AMRX) restricted stock units for Chintu Patel vest?

The 190,632 time-based restricted stock units vest in four equal annual installments starting March 2, 2027. This structure ties continued service to gradual ownership of Amneal’s Class A common stock over four years.

What are the terms of Chintu Patel’s performance-based RSUs at Amneal (AMRX)?

The 354,031 performance-based RSUs vest based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year period. Any earned units vest in full on February 28, 2029, aligning compensation with share price performance.

What is the potential payout range for Amneal (AMRX) performance-based RSUs granted to Chintu Patel?

The payout can range from 0% to 200% of the 354,031 target performance-based RSUs. The number of shares ultimately received depends on stock price performance over the three-year performance period defined in the award terms.

When do Chintu Patel’s Amneal (AMRX) performance-based RSUs vest if earned?

Any performance-based restricted stock units that are earned vest in full on February 28, 2029. This date marks the end of the three-year performance period used to determine the number of shares earned under the award.

What does each restricted stock unit represent for Amneal (AMRX) Class A shares?

Each restricted stock unit and each performance-based restricted stock unit represents a contingent right to receive one share of Amneal’s Class A common stock. Actual receipt depends on meeting vesting and, for performance units, stock price performance conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Chintu

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/02/2026		A		190,632		(2)	(2)	Class A Common Stock	190,632	$0	190,632	D
Performance-Based Restricted Stock Units	(3)	03/02/2026		A		354,031		(4)	(4)	Class A Common Stock	354,031	$0	354,031	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

4. Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.